12th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London have conducted a population-based study to explore the risk factors associated with COVID-19 susceptibility and survival in patients with a history of diseases of the liver, pancreas or biliary system – also known as hepato-pancreato-biliary (HPB) diseases – in East London.
Read more5th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and Edge Hill University are set to investigate how artificial intelligence could be used to improve early diagnosis of pancreatic cancer.
Read more12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more3rd October 2019
A lifetime model evaluating the financial, health and social impact of multigene testing at diagnosis for all breast cancer patients was found to save lives and be extremely cost-effective for both UK and US health systems.
Read more2nd April 2019
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.
Read more14th January 2019
Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to showcase our blood cancer research.
Read more